Results 11 to 20 of about 1,016,262 (299)

Effects of an anticarcinogenic Bowman-Birk protease inhibitor on purified 20S proteasome and MCF-7 breast cancer cells. [PDF]

PLoS ONE, 2014
Proteasome inhibitors have been described as an important target for cancer therapy due to their potential to regulate the ubiquitin-proteasome system in the degradation pathway of cellular proteins.
Larissa da Costa Souza, Ricardo Camargo, Marilene Demasi, Jaime Martins Santana, Cézar Martins de Sá, Sonia Maria de Freitas   +5 more
doaj   +2 more sources

Cardiovascular toxicity of proteasome inhibitors in multiple myeloma therapy

, 2022
The treatment for multiple myeloma has advanced significantly over the past few decades. Proteasome inhibitors have become the cornerstone of the treatment of multiple myeloma.
Huang, Shan, Tse, Gary, Xie, Bingxin, Liu, Tong, Zhang, Nan, Zheng, Yi, Liu, Zhiqiang   +6 more
core   +2 more sources

Proteasome inhibitors

Biochemical Pharmacology, 2015
Proteasome inhibitors have a 20 year history in cancer therapy. The first proteasome inhibitor, bortezomib (Velcade, PS-341), a break-through multiple myeloma treatment, moved rapidly through development from bench in 1994 to first approval in 2003. Bortezomib is a reversible boronic acid inhibitor of the chymotrypsin-like activity of the proteasome ...
Teicher, Beverly A., Tomaszewski, Joseph E.   +1 more
openaire   +4 more sources

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma [PDF]

, 2023
Proteasome inhibition is a highly effective treatment for multiple myeloma (MM). However, virtually all patients develop proteasome inhibitor resistance which is associated with a poor prognosis.
Ramberger, E., Liebig, S., Jan Krönke, Uta Margareta Demel, Guus J. J. E. Heynen, Krüger, J., Ulrich Keller, Janz, M., Bassermann, F., Michael Heider, Schick, M., Florian Bassermann, Baumgartner, F., Dominik Laue, Heynen, G.J.J.E., Laue, D., Patra, U., Axel Nogai, Schäffer, I., Bamopoulos, S.A., Kaiser, M., Josefine Krüger, Markus Schick, Krönke, J., Evelyn Ramberger, Yuen Lam Dora Ng, Heider, M., Braune, J., Murgai, A., Stefan Müller, Wirth, M., Keller, U., Matthias Wirth, Nogai, A., Demel, U.M., Melanie Kaiser, Francis Baumgartner, Upayan Patra, Holz, M., Mertins, P., Arunima Murgai, Philipp Mertins, Martin Janz, Ng, Y.L.D., Jan Braune, Müller, S., Sven Liebig, Maximilian Holz, Isabell Schäffer, Stefanos A. Bamopoulos   +49 more
core   +1 more source

Fluorescence-based proteasome activity profiling [PDF]

, 2011
With the proteasome emerging as a therapeutic target for cancer treatment, accurate tools for monitoring proteasome (inhibitor) activity are in demand.
Jong, A., Rodenko, B., Berkers, C.R., Schuurman, K.G., Ovaa, H., Boris Rodenko, Annemieke de Jong, Celia R. Berkers, Karianne G. Schuurman, Huib Ovaa   +9 more
core   +1 more source

Dss1 Is a 26S Proteasome Ubiquitin Receptor [PDF]

, 2014
The ubiquitin-proteasome system is the major pathway for protein degradation in eukaryotic cells. Proteins to be degraded are conjugated to ubiquitin chains that act as recognition signals for the 26S proteasome.
Hardwick, Kevin G., Hay, Ronald T., Larsen, Ida B., Kragelund, Birthe B., Tatham, Michael H, Rösner, Heike I, Kragelund, Birthe Brandt, Hay, Ronald T, Kragelund, Birthe B, Kriegenburg, Franziska, Tatham, Michael H., Rösner, Heike Ilona, Paraskevopoulos, Konstantinos, Brandstrup, Rikke, Larsen, Ida B, Medina, Bethan; id_orcid, Hartmann-Petersen, Rasmus, Gordon, Colin, Rösner, Heike I., Hardwick, Kevin G, Medina, Bethan   +20 more
core   +1 more source

The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells

Haematologica, 2015
Proteasome inhibitor resistance is a challenge for myeloma therapy. Bortezomib targets the β5 and β1 activity, but not the β2 activity of the proteasome.
Marianne Kraus, Juergen Bader, Paul P. Geurink, Emily S. Weyburne, Anne C. Mirabella, Tobias Silzle, Tamer B. Shabaneh, Wouter A. van der Linden, Gerjan de Bruin, Sarah R. Haile, Eva van Rooden, Christina Appenzeller, Nan Li, Alexei F. Kisselev, Herman Overkleeft, Christoph Driessen   +15 more
doaj   +1 more source

Epoxomicin, a Selective Proteasome Inhibitor, Activates AIM2 Inflammasome in Human Retinal Pigment Epithelium Cells

Antioxidants, 2022
Emerging evidence suggests that the intracellular clearance system plays a vital role in maintaining homeostasis and in regulating oxidative stress and inflammation in retinal pigment epithelium (RPE) cells. Dysfunctional proteasomes and autophagy in RPE
Iswariyaraja Sridevi Gurubaran, Maria Hytti, Kai Kaarniranta, Anu Kauppinen   +3 more
doaj   +1 more source

Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition

BMC Nephrology, 2023
Background Thrombotic microangiopathy (TMA) is a potentially organ and life-threatening condition affecting patients with multiple myeloma (MM). Cases of proteasome inhibitor-induced TMA and specifically carfilzomib-induced TMA have been rarely reported ...
Lorenzo Catanese, Katharina Link, Harald Rupprecht   +2 more
doaj   +1 more source

The proteasome inhibitor MLN-273 blocks exoerythrocytic and erythrocytic development of Plasmodium parasites. [PDF]

, 2005
Protein degradation is regulated during the cell cycle of all eukaryotic cells and is mediated by the ubiquitin-proteasome pathway. Potent and specific peptide-derived inhibitors of the 20S proteasome have been developed recently as anti-cancer agents ...
Weich, N, Lindenthal, C, Chia, Y S, Heussler, Volker, Klinkert, M Q   +4 more
core   +2 more sources